Core Viewpoint - Four Seasons Pharmaceutical (00460) has seen a nearly 4% increase in stock price following the approval of six new specifications for its self-developed polylactic acid facial filler, known as "童颜针" (youthful needle), by the National Medical Products Administration of China, marking a significant advancement in the company's regenerative aesthetic product portfolio [1] Group 1: Company Developments - The newly approved specifications include 60mg, 80mg, 100mg, 110mg, 120mg, and 130mg bottles, expanding the product range and enhancing market offerings [1] - Prior to this expansion, the product had already received approval for three specifications: 45mg, 75mg, and 150mg bottles, catering to different needs such as preventive management, combination therapy, and comprehensive rejuvenation [1] Group 2: Market Impact - The stock price of Four Seasons Pharmaceutical rose by 3.94%, reaching HKD 1.32, with a trading volume of 12.825 million HKD, indicating positive market sentiment following the announcement [1]
港股异动 | 四环医药(00460)涨近4% 近日童颜针新增规格获批上市 进一步完善再生医美产品市场布局